Flipping the script on genetic medicines
We precisely redirect a naturally occurring human protein for therapeutic benefit.
Our bodies naturally use the protein adenosine deaminase acting on RNA, or ADAR, to edit RNA to maintain health. AIRNA’s founders pioneered the idea that ADAR could be harnessed and focused to make precise, intentional changes to RNA to treat disease, without permanently changing a person’s DNA.
We are designing medicines that precisely guide ADAR to a specific RNA location to accurately change one adenosine (A) into an inosine (I), which is read by the body’s genetic machinery as a guanosine (G). The result: modified function of the resulting protein, with potential to reverse or prevent disease.
We are pursuing diseases where the underlying mechanism is well established, has been difficult or impossible to reach with other approaches, and is well-suited to RNA editing.
Recoding life’s software
Our goal is to develop potent genetic medicines with flexible dosing.
Our product candidates are oligonucleotides (short strands of nucleic acids) with proprietary technologies designed for best-in-class editing efficiency and durability, optimal safety, patient-friendly administration, and low and infrequent dosing that is both reversible and repeatable. We believe this approach will be preferred by patients and physicians for its convenient and safe delivery combined with potent and durable protein production.
AIRNA was founded by the scientific pioneers of ADAR editing. Learn about the latest in the field.
partnering
AIRNA has deep expertise in precision RNA editing therapeutics across a range of genetically tractable disease targets. We are interested in strategic collaborations to extend these capabilities to therapeutic areas of mutual interest.
Contact
[email protected]